-
平臺(tái)編號(hào)：bio-68425
-
國(guó)際編號(hào)：CRL-2555?
-
細(xì)胞信息： Panc 04.03
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
Panc 04.03
數(shù)量：大量
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
ATCC Number：CRL-2555?
器官來(lái)源：胰腺
相關(guān)疾?。合侔?br /> 生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
運(yùn)輸方式：凍存運(yùn)輸
年限：70 years adult
細(xì)胞形態(tài)：上皮樣
規(guī)格：0.2ml Designations: Panc 04.03
Depositors: ?EM Jaffee
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens deposited as human
Morphology:epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products:cytokeratins 7 and 18 [50655 ]
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: April 3, 1995
Tumorigenic:Yes
Oncogene:K-ras +
Antigen Expression:MHC class I +; MHC class II - [50655 ]
Blood type O; Rh+
DNA Profile (STR):Amelogenin: X
CSF1PO: 12
D13S317: 11,12
D16S539: 11,12
D5S818: 11
D7S820: 8,12
THO1: 9.3
TPOX: 10,11
vWA: 14,16
Age: 70 years adult
Gender: male
Ethnicity: White
Comments:Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655 ]
The cells have a reported plating efficiency of 80%. [50655 ]
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 20 Units/ml human recombinant insulin, 85%; fetal bovine serum, 15%
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Add media once per week. Fluid change one to two times per week.
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 50.5 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
ATCC Number：CRL-2555?
器官來(lái)源：胰腺
相關(guān)疾?。合侔?br /> 生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
運(yùn)輸方式：凍存運(yùn)輸
年限：70 years adult
細(xì)胞形態(tài)：上皮樣
規(guī)格：0.2ml Designations: Panc 04.03
Depositors: ?EM Jaffee
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens deposited as human
Morphology:epithelial
Source: Organ: pancreas
Disease: adenocarcinoma
Cellular Products:cytokeratins 7 and 18 [50655 ]
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: April 3, 1995
Tumorigenic:Yes
Oncogene:K-ras +
Antigen Expression:MHC class I +; MHC class II - [50655 ]
Blood type O; Rh+
DNA Profile (STR):Amelogenin: X
CSF1PO: 12
D13S317: 11,12
D16S539: 11,12
D5S818: 11
D7S820: 8,12
THO1: 9.3
TPOX: 10,11
vWA: 14,16
Age: 70 years adult
Gender: male
Ethnicity: White
Comments:Panc 04.03 is a pancreatic adenocarcinoma epithelial cell line derived, in 1995, from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma.
The cell line exhibits a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655 ]
The cells have a reported plating efficiency of 80%. [50655 ]
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 20 Units/ml human recombinant insulin, 85%; fetal bovine serum, 15%
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Add media once per week. Fluid change one to two times per week.
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 50.5 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
